The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Exploring treatment resistance in myeloma with MRD
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, gives an outline of a study analyzing MRD profiling and treatment resistance in patients with standard- and high-risk myeloma, enrolled on the GEM2012MENOS65 trial (NCT01916252). MRD was evaluated using next-generation flow cytometry. Undetectable MRD after VRD (bortezomib, lenalidomide and dexamethasone) induction, transplant and VRD consolidation, was found to overcome poor prognosis in patients with high-risk cytogenetic abnormalities. Furthermore, characterization of MRD cells revealed greater clonal selection in standard-risk myeloma and greater genomic instability in high-risk patients. This interview took place during the 2021 European Myeloma Network (EMN) congress.
